Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.

Literature DB >> 12021376

Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.

Paul W H I Parren¹, Tom W Geisbert, Toshiaki Maruyama, Peter B Jahrling, Dennis R Burton.

Abstract

A neutralizing human monoclonal antibody, KZ52, protects guinea pigs from lethal Ebola Zaire virus challenge. Administration before or up to 1 h after challenge resulted in dose-dependent protection by the antibody. Interestingly, some antibody-treated animals survived despite developing high-level viremia, suggesting that the mechanism of protection by KZ52 may extend beyond reduction of viremia by virus neutralization. KZ52 is a promising candidate for immunoprophylaxis of Ebola virus infection.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2002 PMID： 12021376 PMCID： PMC136210 DOI： 10.1128/jvi.76.12.6408-6412.2002

Source DB: PubMed Journal: J Virol ISSN： 0022-538X Impact factor: 5.103

33 in total

1. Ebola virus can be effectively neutralized by antibody produced in natural human infection.

Authors: T Maruyama; L L Rodriguez; P B Jahrling; A Sanchez; A S Khan; S T Nichol; C J Peters; P W Parren; D R Burton
Journal: J Virol Date: 1999-07 Impact factor: 5.103

2. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival.

Authors: R F Sadek; A S Khan; G Stevens; C J Peters; T G Ksiazek
Journal: J Infect Dis Date: 1999-02 Impact factor: 5.226

Review 3. An introduction to Ebola: the virus and the disease.

Authors: C J Peters; J W LeDuc
Journal: J Infect Dis Date: 1999-02 Impact factor: 5.226

4. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

Authors: J R Mascola; M G Lewis; G Stiegler; D Harris; T C VanCott; D Hayes; M K Louder; C R Brown; C V Sapan; S S Frankel; Y Lu; M L Robb; H Katinger; D L Birx
Journal: J Virol Date: 1999-05 Impact factor: 5.103

5. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.

Authors: M Bray; K Davis; T Geisbert; C Schmaljohn; J Huggins
Journal: J Infect Dis Date: 1999-02 Impact factor: 5.226

6. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections.

Authors: N M Kudoyarova-Zubavichene; N N Sergeyev; A A Chepurnov; S V Netesov
Journal: J Infect Dis Date: 1999-02 Impact factor: 5.226

7. Recombinant human monoclonal antibodies to Ebola virus.

Authors: T Maruyama; P W Parren; A Sanchez; I Rensink; L L Rodriguez; A S Khan; C J Peters; D R Burton
Journal: J Infect Dis Date: 1999-02 Impact factor: 5.226

8. Pathogenesis of experimental Ebola virus infection in guinea pigs.

Authors: B M Connolly; K E Steele; K J Davis; T W Geisbert; W M Kell; N K Jaax; P B Jahrling
Journal: J Infect Dis Date: 1999-02 Impact factor: 5.226

9. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections.

Authors: P B Jahrling; T W Geisbert; J B Geisbert; J R Swearengen; M Bray; N K Jaax; J W Huggins; J W LeDuc; C J Peters
Journal: J Infect Dis Date: 1999-02 Impact factor: 5.226

10. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge.

Authors: L Vanderzanden; M Bray; D Fuller; T Roberts; D Custer; K Spik; P Jahrling; J Huggins; A Schmaljohn; C Schmaljohn
Journal: Virology Date: 1998-06-20 Impact factor: 3.616

100 in total

1. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.

Authors: J Brian Kimble; Delphine C Malherbe; Michelle Meyer; Bronwyn M Gunn; Marcus M Karim; Philipp A Ilinykh; Mathieu Iampietro; Khaled S Mohamed; Surendra Negi; Pavlo Gilchuk; Kai Huang; Yuri I Wolf; Werner Braun; James E Crowe; Galit Alter; Alexander Bukreyev
Journal: J Virol Date: 2019-02-05 Impact factor: 5.103

2. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

Authors: Larry Zeitlin; James Pettitt; Corinne Scully; Natasha Bohorova; Do Kim; Michael Pauly; Andrew Hiatt; Long Ngo; Herta Steinkellner; Kevin J Whaley; Gene G Olinger
Journal: Proc Natl Acad Sci U S A Date: 2011-12-05 Impact factor: 11.205

3. A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.

Authors: Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Gary P Kobinger; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal: Mol Pharm Date: 2011-12-15 Impact factor: 4.939

4. Development and characterization of rabbit and mouse antibodies against ebolavirus envelope glycoproteins.

Authors: Wu Ou; Josie Delisle; Krishnamurthy Konduru; Steven Bradfute; Sheli R Radoshitzky; Cary Retterer; Krishna Kota; Sina Bavari; Jens H Kuhn; Peter B Jahrling; Gerardo Kaplan; Carolyn A Wilson
Journal: J Virol Methods Date: 2011-04-13 Impact factor: 2.014